Delving into the Latest Updates on Telix Pharmaceuticals (US), Inc. with Synapse

概览

疾病领域	数量

神经系统疾病	1
肿瘤	1

排名前五的药物类型	数量

诊断用放射药物	1
多肽偶联核素	1

排名前五的靶点	数量

PSMA(前列腺癌特异性膜抗原)	1

关联

1

项与 Telix Pharmaceuticals (US), Inc. 相关的药物

Gallium GA-68 Gozetotide

靶点

PSMA

作用机制

PSMA抑制剂 [+1]

在研机构

Telix Pharmaceuticals (US), Inc. [+11]

原研机构

The University of California, San Francisco

在研适应症

转移性去势抵抗性前列腺癌 [+11]

非在研适应症

前列腺腺癌 [+1]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2020-12-01

1

项与 Telix Pharmaceuticals (US), Inc. 相关的临床试验

CTR20230844 / Recruiting临床3期

一项评估68Ga-PSMA-11 PET/CT或PET/MRI在前列腺癌生化复发患者中的诊断有效性和安全性的前瞻性、开放性、单臂、多中心研究

主要目的：评估 68Ga-PSMA-11 PET/CT 或 PET/MRI 对前列腺癌生化复发患者的诊断有效性。次要目的：评估 68Ga-PSMA-11 用于中国前列腺癌生化复发患者的安全性和耐受性；评估 68Ga-PSMA-11 PET/CT 或 PET/MRI 成像对治疗决策的影响。

开始日期2023-06-16

申办/合作机构

Telix Pharmaceuticals (US), Inc.

[+2]

100 项与 Telix Pharmaceuticals (US), Inc. 相关的临床结果

登录后查看更多信息

0 项与 Telix Pharmaceuticals (US), Inc. 相关的专利（医药）

登录后查看更多信息

1

项与 Telix Pharmaceuticals (US), Inc. 相关的文献（医药）

2023-10-01·The British Journal of Radiology

The role of clinical imaging in oncology drug development: progress and new challenges

Review

作者: Galette, Paul ; Murphy, Philip Stephen ; Patel, Neel ; Brown, Andrew P ; van der Aart, Jasper ; Janiczek, Robert L

AbstractIn 2008, the role of clinical imaging in oncology drug development was reviewed. The review outlined where imaging was being applied and considered the diverse demands across the phases of drug development. A limited set of imaging techniques was being used, largely based on structural measures of disease evaluated using established response criteria such as response evaluation criteria in solid tumours. Beyond structure, functional tissue imaging such as dynamic contrast-enhanced MRI and metabolic measures using [18F]flourodeoxyglucose positron emission tomography were being increasingly incorporated. Specific challenges related to the implementation of imaging were outlined including standardisation of scanning across study centres and consistency of analysis and reporting. More than a decade on the needs of modern drug development are reviewed, how imaging has evolved to support new drug development demands, the potential to translate state-of-the-art methods into routine tools and what is needed to enable the effective use of this broadening clinical trial toolset. In this review, we challenge the clinical and scientific imaging community to help refine existing clinical trial methods and innovate to deliver the next generation of techniques. Strong industry–academic partnerships and pre-competitive opportunities to co-ordinate efforts will ensure imaging technologies maintain a crucial role delivering innovative medicines to treat cancer.

100 项与 Telix Pharmaceuticals (US), Inc. 相关的药物交易

登录后查看更多信息

100 项与 Telix Pharmaceuticals (US), Inc. 相关的转化医学

登录后查看更多信息